238 related articles for article (PubMed ID: 28901637)
61. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.
Khan AB; Barrington SF; Mikhaeel NG; Hunt AA; Cameron L; Morris T; Carr R
Blood; 2013 Jul; 122(1):61-7. PubMed ID: 23660958
[TBL] [Abstract][Full Text] [Related]
62. Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
Schaefer NG; Strobel K; Taverna C; Hany TF
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):60-7. PubMed ID: 17021808
[TBL] [Abstract][Full Text] [Related]
63. The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma.
El-Najjar I; Montoto S; McDowell A; Matthews J; Gribben J; Szyszko TA
Nucl Med Commun; 2014 Mar; 35(3):311-5. PubMed ID: 24323311
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset.
Luan D; Wu Y; Goldstein J; Rutherford S; Leonard JP; Martin P
Leuk Lymphoma; 2021 Aug; 62(8):1850-1859. PubMed ID: 33627025
[TBL] [Abstract][Full Text] [Related]
65. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
66. 18f-Fluorodeoxyglucose Positron Emission Tomography Versus Bone Marrow Biopsy for the Evaluation of Bone Marrow Infiltration in Newly Diagnosed Lymphoma Patients.
Aguado-Vázquez TM; Olivas-Martínez A; Cancino-Ramos U; Zúñiga-Tamayo DA; Lome-Maldonado MDCA; Rivas-Vera S; García-Pérez FO; Candelaria-Hernández MG
Rev Invest Clin; 2020 May; 73(5):. PubMed ID: 33048916
[TBL] [Abstract][Full Text] [Related]
67. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
[TBL] [Abstract][Full Text] [Related]
68. Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test?
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Acta Oncol; 2015 Jan; 54(1):67-72. PubMed ID: 25263078
[TBL] [Abstract][Full Text] [Related]
69. The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma.
Kim HY; Kim JS; Choi DR; Kim HS; Kwon JH; Jang GD; Kim JH; Jung JY; Song HH; Lee YK; Min SK; Hwang HS; Kim HJ; Zang DY; Kim HJ
Cancer Res Treat; 2015 Jul; 47(3):458-64. PubMed ID: 25648095
[TBL] [Abstract][Full Text] [Related]
70. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis.
Chen YK; Yeh CL; Tsui CC; Liang JA; Chen JH; Kao CH
Clin Nucl Med; 2011 Jul; 36(7):553-9. PubMed ID: 21637057
[TBL] [Abstract][Full Text] [Related]
71. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration].
Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490
[TBL] [Abstract][Full Text] [Related]
72. The relation of bone marrow scintigraphy and unilateral bone marrow biopsy in malignant lymphoma.
Esmaili J; Safaee SR; Sharifian R; Shoeybi S; Gholamrezanezhad A
Hell J Nucl Med; 2005; 8(2):125-8. PubMed ID: 16142255
[TBL] [Abstract][Full Text] [Related]
73. Staging DLBCL: bone marrow biopsy or PET-CT?
Avigdor A
Blood; 2013 Jul; 122(1):4-5. PubMed ID: 23828884
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging.
Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Staudenherz A; Senn D; Raderer M; Weber M; Simonitsch-Klupp I; Mayerhoefer ME
PLoS One; 2016; 11(10):e0164118. PubMed ID: 27723817
[TBL] [Abstract][Full Text] [Related]
75. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.
Adams HJ; Nievelstein RA; Kwee TC
Blood Rev; 2015 Nov; 29(6):417-25. PubMed ID: 26113144
[TBL] [Abstract][Full Text] [Related]
76. Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes.
Döbert N; Menzel C; Berner U; Hamscho N; Wördehoff N; Mitrou P; Grünwald F
Cancer Biother Radiopharm; 2003 Aug; 18(4):565-71. PubMed ID: 14503951
[TBL] [Abstract][Full Text] [Related]
77. [Diagnostic value of FDG-PET in the detection of bone marrow involvement in patients with diffuse large B-cell lymphoma].
Zhang X; Fan W; Lin XP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):832-5. PubMed ID: 19176040
[TBL] [Abstract][Full Text] [Related]
78. Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy.
Li X; An C; Zhang W
BMC Cancer; 2022 Jun; 22(1):614. PubMed ID: 35659208
[TBL] [Abstract][Full Text] [Related]
79. Prospective observational study on diagnostic accuracy of whole-body MRI in solid small round cell tumours.
Kembhavi SA; Rangarajan V; Shah S; Qureshi S; Arora B; Juvekar S; Laskar S; Vora T; Chinnaswamy G; Ramadwar M; Kurkure P
Clin Radiol; 2014 Sep; 69(9):900-8. PubMed ID: 24863003
[TBL] [Abstract][Full Text] [Related]
80. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
